Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/14/2025

Evaluation and Management of Anemia of Chronic Disease

Diagnostic Criteria and Initial Evaluation

  • Anemia of chronic disease is defined as hemoglobin <135 g/L in adult males and <120 g/L in adult females in the context of chronic inflammatory, infectious, or neoplastic disorders, according to the Kidney International Supplements 1
  • Initial laboratory evaluation should include complete blood count with red cell indices, reticulocyte count to assess bone marrow response, and iron studies including serum iron, ferritin, transferrin saturation, and total iron-binding capacity, as recommended by the Kidney International Supplements 1 and Praxis Medical Insights 2

Distinguishing Features of Anemia of Chronic Disease

  • Characteristic laboratory findings include low serum iron, low or normal transferrin and total iron-binding capacity, low transferrin saturation, and normal or elevated ferritin, as reported by the Kidney International Supplements 3 and Praxis Medical Insights 4
  • Low reticulocyte count or index is also a characteristic finding, according to the Kidney International Supplements 1 and Praxis Medical Insights 2

Additional Testing Based on Clinical Context

  • Evaluate for underlying conditions commonly associated with anemia of chronic disease, including chronic kidney disease, as recommended by the Kidney International Supplements 1 and Praxis Medical Insights 2
  • Additional tests to consider include kidney function tests, vitamin B12 and folate levels, and hepcidin levels, as suggested by Praxis Medical Insights 2

Management Approach

  • Treatment of underlying condition is the primary management strategy, supplemented by targeted interventions for the anemia itself when clinically significant, according to Praxis Medical Insights 2
  • Iron supplementation may be considered if there is evidence of concomitant iron deficiency, as recommended by Praxis Medical Insights 4
  • Erythropoiesis-stimulating agents may be considered in severe or symptomatic anemia, particularly in chronic kidney disease, but with caution and careful monitoring, as suggested by Praxis Medical Insights 2
  • Blood transfusions should be reserved for severe, symptomatic anemia or hemodynamic instability, according to Praxis Medical Insights 2

Common Pitfalls and Considerations

  • Ferritin is an acute phase reactant and may be elevated in inflammatory states despite iron deficiency, as reported by the Kidney International Supplements 3 and Praxis Medical Insights 4
  • Standard definitions of anemia may not apply to certain populations, such as pregnant women, elderly, those living at high altitude, or smokers, according to the Kidney International Supplements 1
  • Consider hematology consultation for complex or refractory cases, as recommended by the Kidney International Supplements 1

REFERENCES

1
2

Investigation of Severe Anemia [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

3
4

Diagnosis and Management of Microcytic Anemia [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025